Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Nov 3, 2025, 3:48 PM EST
Seelos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 0.29 | 3 | 15.53 | 78.73 | 15.66 | 10.26 |
Cash & Short-Term Investments | 0.29 | 3 | 15.53 | 78.73 | 15.66 | 10.26 |
Cash Growth | -94.97% | -80.71% | -80.27% | 402.71% | 52.64% | 24330.95% |
Receivables | 0.19 | 0.76 | - | - | - | - |
Prepaid Expenses | 1.71 | 1.57 | 6.94 | 4.54 | 1.79 | 0.84 |
Other Current Assets | 0.15 | 0.08 | 0.2 | 0.19 | 0.04 | - |
Total Current Assets | 2.33 | 5.4 | 22.67 | 83.46 | 17.49 | 11.1 |
Property, Plant & Equipment | 0.05 | 0.02 | 0.07 | 0.04 | - | - |
Total Assets | 2.38 | 5.42 | 22.75 | 83.5 | 17.49 | 11.1 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Accounts Payable | 15.69 | 16.4 | 3.63 | 1.69 | 1.89 | 0.8 |
Accrued Expenses | 4.36 | 2.52 | 7.28 | 3.73 | 1.92 | 1.92 |
Current Portion of Long-Term Debt | 10.11 | 14.21 | 11.87 | 1.03 | 2.43 | - |
Current Portion of Leases | 0.05 | 0.02 | 0.06 | 0.04 | - | - |
Other Current Liabilities | 0.31 | 5.78 | 2.33 | 1.8 | 1.19 | 8.06 |
Total Current Liabilities | 30.51 | 38.93 | 25.16 | 8.29 | 7.43 | 10.78 |
Long-Term Debt | - | - | 8.18 | 17.89 | 7.29 | - |
Long-Term Leases | - | - | 0.02 | - | - | - |
Other Long-Term Liabilities | - | - | - | - | 0.2 | 0.33 |
Total Liabilities | 30.51 | 38.93 | 33.36 | 26.18 | 14.92 | 11.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Common Stock | 0 | 0.01 | 0 | 0.11 | 0.05 | 0.03 |
Additional Paid-In Capital | 225.44 | 219.11 | 204.13 | 198.43 | 77.68 | 56.03 |
Retained Earnings | -253.58 | -252.63 | -214.74 | -141.21 | -75.16 | -56.06 |
Shareholders' Equity | -28.13 | -33.51 | -10.61 | 57.32 | 2.57 | -0.01 |
Total Liabilities & Equity | 2.38 | 5.42 | 22.75 | 83.5 | 17.49 | 11.1 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Total Debt | 10.16 | 14.23 | 20.12 | 18.96 | 9.72 | - |
Net Cash (Debt) | -9.86 | -11.23 | -4.59 | 59.78 | 5.94 | 10.26 |
Net Cash Growth | - | - | - | 906.67% | -42.13% | - |
Net Cash Per Share | -113.46 | -293.39 | -165.66 | 2525.50 | 509.35 | - |
Filing Date Shares Outstanding | 0.37 | 0.11 | 0.03 | 0.03 | 0.02 | 0.01 |
Total Common Shares Outstanding | 0.21 | 0.08 | 0.03 | 0.03 | 0.01 | 0.01 |
Working Capital | -28.18 | -33.53 | -2.48 | 75.17 | 10.07 | 0.32 |
Book Value Per Share | -135.50 | -437.92 | -380.21 | 2086.45 | 181.10 | -0.99 |
Tangible Book Value | -28.13 | -33.51 | -10.61 | 57.32 | 2.57 | -0.01 |
Tangible Book Value Per Share | -135.50 | -437.92 | -380.21 | 2086.45 | 181.10 | -0.99 |